Memorial Sloan Kettering Cancer Center;Academia Sinica
发明人:
申请号：
EP16837721.6
公开号：
EP3337784A4
申请日:
2016.08.17
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.
